WT1 and hematopoietic and lymphoid cell neoplasm: An expression analysis in the 26 of the hematological cancer cell lines and 53 primary AML samples revealed GATA-2 and WT1/AWT1 co-expressed in 96% cases (51/56) consistent with this mechanism being a regulator of expression at the locus (Additional file 5: Figure S3).